Low-Dose, Single-Agent Temsirolimus for Relapsed Mantle Cell Lymphoma: A Phase 2 Trial in the North Central Cancer Treatment Group

BACKGROUND: The objective of this study was to test a low dose of (25 mg weekly) of the mammalian target of rapamycin kinase inhibitor temsirolimus for patients with relapsed mantle cell lymphoma (MCL). METHODS: Patients with relapsed or refractory MCL were eligible to receive temsirolimus 25 mg int...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Ansell, Stephen M., Inwards, David J., Rowland, Kendrith M., Flynn, Patrick J., Morton, Roscoe F., Moore, Dennis F., Kaufmann, Scott H., Ghobrial, Irene, Kurtin, Paul J., Maurer, Matthew, Allmer, Christine, Witzig, Thomas E.
Формат: Artigo
Язык:Inglês
Опубликовано: 2008
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3627208/
https://ncbi.nlm.nih.gov/pubmed/18543327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23580
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы